Fig. 5: RBM15 confers osimertinib resistance in H1975-OR and PDO1-OR with the EMT phenotype. | Oncogene

Fig. 5: RBM15 confers osimertinib resistance in H1975-OR and PDO1-OR with the EMT phenotype.

From: RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1

Fig. 5

A, B GSEA pathway enrichment was performed using DEGs. C Volcano plot of RNA-seq results displaying DEGs in H1975 and H1975-OR. D, E Western blot and immunofluorescence detection of protein expression of EMT-related indicators (scale bar: 50 μm). T test. F Immunofluorescence detection of protein expression of EMT-related indicators in PDO-OS and PDO1-OR (scale bar: 25 μm). T test. G Change in CDH1, ZEB1, AXL, and RBM15 expression in osimertinib refractory tissues and matched pre-treatment tissues. H–J Spearman’s correlation of change in CDH1, ZEB1, AXL, and RBM15 expression in eight patients with matched pre- and post-osimertinib treatment. Pearson test. K, L Western blot and immunofluorescence assays reveal changes in protein expression of EMT indicators in H1975-OR and PDO1-OR after RBM15 knockdown. M Immunofluorescence assays reveal changes in protein expression of EMT indicators in PDO1-OR after RBM15 and SPOCK1 knockdown (scale bar: 50 μm). T test. Error bars represent the means ± SDs. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page